Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of BRII-179 in chronic hepatitis B virus infection
CTR20213100Phase 2Completed
- Sponsor
- Brii Biosciences
- Start
- Dec 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BRII-179 in Chronic Hepatitis B (CHB), sponsored by Brii Biosciences. Started Dec 2021; status: completed.
02
Drugs
BRII-179
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20213100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20213100.